Please login to the form below

Not currently logged in
Email:
Password:

ataluren

This page shows the latest ataluren news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer unimpressed with PTC’s Translarna

FDA reviewer unimpressed with PTC’s Translarna

The dossier for Translarna (ataluren) has already been in front of the FDA twice and rejected both times, and analysts from Credit Suisse and JP Morgan both suggested that the chances

Latest news

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2014 Pharma deals during January 2014

    In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m. ... Ataluren was in clinical development for the treatment of Duchenne muscular dystrophy caused by nonsense mutations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics